RxDoctor Payments Data

Mamoun Abdoh, MD

Pulmonary Disease · Cleveland, OHNPI 1982868196

Payments from drug & device makers

$4,448in general payments, 2019–2025

Across 18 payments — averaging $247.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • AstraZeneca$135
  • Merck$124
  • Amgen$121
  • Insmed, Inc.$46
  • Pulmonx Corporation$19
  • plus $43 from 3 others

What the payments were for

  • Travel & lodging$85719%
  • Food & beverage$59113%
  • Education$3,00067%

General payments by program year

20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical9$3,960
AstraZeneca1$135
Merck1$124
Amgen1$121
Insmed, Inc.2$46
Pulmonx Corporation1$19
Sanofi1$16
Harmony Biosciences LLC1$14
Inogen, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,448 in reported general payments places this provider in the 60th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$80,705
Medicare patients
448
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$60,805
Spiriva RespimatTiotropium Bromide91$52,978
Stiolto RespimatTiotropium Br/Olodaterol Hcl45$33,981
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$21,836
Incruse ElliptaUmeclidinium Bromide48$16,014
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate47$12,046
Breo ElliptaFluticasone/Vilanterol24$11,017
SymbicortBudesonide/Formoterol Fumarate29$9,868
DuleraMometasone/Formoterol21$9,028
Arnuity ElliptaFluticasone Furoate26$6,414
Albuterol Sulfate HfaAlbuterol Sulfate188$5,150
Qvar RedihalerBeclomethasone Dipropionate13$4,649
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$4,477
Wixela InhubFluticasone Propion/Salmeterol11$879
Ventolin HfaAlbuterol Sulfate12$691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$135$9,86829 claims
MerckDulera$124$9,02821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →